ACOR Acorda Therapeutics Inc.

+0.30  (1%)
Previous Close 23.05
Open 23.20
Price To book 1.58
Market Cap 1089293822
Shares 46,650,699
Volume 419,615
Short Ratio 7.38
Av. Daily Volume 820,841

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Improve walking in patients with multiple sclerosis
Phase 2 to be initiated by the end of 2017.
Phase 3 data due 1Q 2018.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017 (i.e. NDA not accepted).
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  2. Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference
  3. Should You Buy Acorda Therapeutics Inc (ACOR) Now?
  4. Acorda Therapeutics Earns RS Rating Upgrade
  5. INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.
  6. ETFs with exposure to Acorda Therapeutics, Inc. : September 7, 2017
  7. Stocks Showing Rising Market Leadership: Acorda Therapeutics Earns 83 RS Rating
  8. ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm
  9. Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
  10. Featured Company News – Acorda Therapeutics Adopts Poison Pill
  11. Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : September 2, 2017
  12. Acorda Adopts Shareholder Rights Plan
  13. Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update
  14. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.
  15. AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
  16. FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
  17. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics Inc. (ACOR)
  18. Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : August 30, 2017
  19. Today's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc.